Clinical trial • Phase III • Gastroenterology|Endocrinology
Eloralintide for Hepatic impairment
Phase III trial of Eloralintide for Hepatic impairment. 20 participants.
Overview
- Trial Therapeutic Area
- Gastroenterology|Endocrinology
- Trial Disease
- Hepatic impairment
- Trial Stage
- Phase III
- Drug Modality
- Peptide/protein/enzyme
Key dates
- Initial CTIS Submission Date
- 15-01-2026
- First CTIS Authorization Date
- 14-04-2026
Trial design
Phase III trial across 1 site in Hungary.
- Target Sample Size
- 20
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 10
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
Hungary
- Earliest CTIS Part Ii Submission Date
- 20-02-2026
- Latest Decision Or Authorization Date
- 14-04-2026
- Processing Time Days
- 53
- Number Of Sites
- 1
- Number Of Participants
- 12
Sites
- Site Name
- CRU Hungary Kft.
- Contact Person Name
- Geza Lakner
- Contact Person Email
- glakner@cruint.com
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- Eloralintide
- Active Substance
- Eloralintide
- Modality
- Peptide/protein/enzyme
Related trials
Other published trials that may interest you.
- Lepodisiran for Hepatic impairment
- NNC0487-0111 for Hepatic impairment
- (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for Nonalcoholic steatohepatitis (NASH) | Liver fibrosis
- Vonafexor for Healthy volunteers|Renal impairment|Metabolic dysfunction-associated steatohepatitis (MASH)
- Bupropion hydrochloride; Naltrexone hydrochloride for Obesity|Weight regain after bariatric surgery